The UK has approved its second weight-loss pill, orforglipron, known commercially as Foundayo, for managing obesity and type 2 diabetes. The Medicines and Healthcare products Regulatory Agency (MHRA) authorized the drug, making Britain the first European nation to approve it outside of the United States.
Key Takeaways
The UK has approved its second weight-loss pill, orforglipron (Foundayo), for use in managing obesity and type 2 diabetes. The Medicines and Healthcare products Regulatory Agency (MHRA) authorized the drug, which is not yet available on the NHS but will be evaluated by NICE for cost-effectiveness.
- Orforglipron helps patients lose around 12.4% of body weight after 16 months
- Approved for those with BMI over 30 or BMI over 27 with a weight-related condition
- Not yet available on the NHS; private prescriptions only
- First European nation to approve the drug, following US approval earlier this year
⚖
▼Source Claims Check
High ConsensusAll 3 publishers report consistent facts across 4 key claims.
| Claim | Status | Reason | |
|---|---|---|---|
| Weight Loss Percentage | Broad Agreement | 12.4% weight reduction in 16 months | |
| Bmi Eligibility Criteria | Broad Agreement | >30 or >27 with health condition | |
| Availability On Nhs | Broad Agreement | Not yet available; NICE evaluation pending | |
| Approval Timeline In Uk | Broad Agreement | Approved two months after Wegovy pill |
Weight Loss Percentage
Broad Agreement12.4% weight reduction in 16 months
Bmi Eligibility Criteria
Broad Agreement>30 or >27 with health condition
Availability On Nhs
Broad AgreementNot yet available; NICE evaluation pending
Approval Timeline In Uk
Broad AgreementApproved two months after Wegovy pill
This analysis is AI-generated and may not perfectly represent each source's reporting. Always read the original articles for full context.
The approval comes just two months after the MHRA greenlit Novo Nordisk's Wegovy pill. Clinical trials showed that orforglipron helped patients lose an average of 12.4% of their body weight—approximately 27 pounds (two stone)—over 16 months, per Daily Mail. The drug is intended for individuals with a body mass index (BMI) over 30, or those with a BMI over 27 and a weight-related health condition. It will also be available to type 2 diabetes patients who need assistance controlling their blood sugar levels.
The MHRA emphasized that the drug's safety, quality, and effectiveness were rigorously assessed. Julian Beach, executive director of healthcare quality and access at the MHRA, stated that while this is a prescription-only medication, its approval marks a significant step forward in obesity treatment. However, orforglipron will not be immediately available on the NHS. According to Sky News, it must first undergo an evaluation by the National Institute for Health and Care Excellence (NICE) to determine cost-effectiveness before becoming accessible through the public health system.
The drug is manufactured by Eli Lilly, which has positioned Foundayo as a competitor to Novo Nordisk's Wegovy pill. Unlike Wegovy, Foundayo can be taken at any time of the day without food or water restrictions, according to CNBC. This flexibility may contribute to its appeal in the weight-loss market. The MHRA also noted that buying GLP-1 medicines from unregulated sellers carries serious health risks and should only be obtained through registered pharmacies with a prescription.
How this summary was created
This summary synthesizes reporting from 3 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.